An interventional study of Probiotics (L. reuteri DSM 17938 and L. reuteri DSM 33633) and Placebo in Virus Diseases in Children, sponsored by Milosevits Gergely. Recruiting at 1 site in Hungary. Open to participants aged 4 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Milosevits Gergely · Not applicable, Interventional, and Supportive care
This study investigates the effect of Limosilactobacillus reuteri probiotic strains (DSM 17938 and DSM 33633) on symptoms of viral upper-respiratory tract infections in children.
Milosevits Gergely is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study product containing L. reuteri (DSM 17938 and DSM 33633) taken orally once in the morning and once in the evening, each time 5 drops.
Dietary Supplement: Probiotics (L. reuteri DSM 17938 and L. reuteri DSM 33633)
Placebo taken orally once in the morning and once in the evening, each time 5 drops.
Other: Placebo
Probiotics drops (L. reuteri DSM 17938 and L. reuteri DSM 33633) with vitamin D3 will be manufactured and delivered by BioGaia AB as oil suspension.
Placebo product contains vitamin D3 and is identical to the active product but lacks L. reuteri.
Percent of observation periods with absence of symptoms in children 4 years to 17 years old with symptoms of viral upper-respiratory tract infection
Time frame: 14 days
Duration of symptoms
Duration of symptoms (runny nose, stuffy nose, sneezing, sore throat, cough) measured from baseline and to end of intervention (14 completed days of intervention).
Time frame: 14 completed days of intervention
Severity of symptoms
Severity of symptoms (runny nose, stuffy nose, sneezing, sore throat, cough), recorded in a "Symptom Diary" based on the clinically validated "Wisconsin Upper Respiratory Symptom Survey 11" (WURSS-11), but modified according to the study's characteristics.
Time frame: 14 completed days of intervention
Duration of fever
Duration of fever, defined as the total number of hours that the child has a core temperature \>38oC measured twice per day measured from baseline and to end of intervention (14 completed days of intervention).
Time frame: 14 completed days of intervention
Amount of anti-pyretic and analgesic medication
Amount of anti-pyretic and analgesic medication, such as NSAIDs used from baseline and to end of intervention (14 completed days of intervention)
Time frame: 14 completed days of intervention
Number of children receiving antibiotic treatment
Number of children receiving antibiotic treatment in each treatment group measured from baseline and to end of intervention (14 completed days of intervention).
Time frame: 14 completed days of intervention
Total amount of days of antibiotic use
Total amount of days of antibiotic use during the study, reported during the whole duration of the study in a the "Symptom Diary" measured from baseline and to end of intervention (14 completed days of intervention).
Time frame: 14 completed days of intervention
Number of unplanned medical visits
Number of unplanned medical visits (other than "Visit 1 and 2"). This outcome is defined as the total amount of medical office visits or emergency visits related to the infection, measured from baseline and to end of intervention (14 completed days of intervention)
Time frame: 14 completed days of intervention
Days of absences from day care center/school.
This outcome is defined as the total amount of days of absences from the day care centre during the study, due to the presence of episodes of URTI, measured from baseline and to end of intervention (14 completed days of intervention).
Time frame: 14 completed days of intervention
Safety of study product
This outcome includes registration of all adverse events, serious adverse events and monitoring of vital signs.
Time frame: 14 completed days of intervention
Plan to share: No
Started Oct 2026 (actual). Primary completion is estimated for Mar 2028, 17 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.